0001193125-23-138911.txt : 20230509 0001193125-23-138911.hdr.sgml : 20230509 20230509073603 ACCESSION NUMBER: 0001193125-23-138911 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 23900003 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 d450885d8k.htm 8-K 8-K
XOMA Corp DE false 0000791908 0000791908 2023-05-09 2023-05-09 0000791908 us-gaap:CommonStockMember 2023-05-09 2023-05-09 0000791908 us-gaap:SeriesAPreferredStockMember 2023-05-09 2023-05-09 0000791908 us-gaap:SeriesBPreferredStockMember 2023-05-09 2023-05-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): May 9, 2023

 

 

XOMA CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

 

 

DELAWARE   001-39801   52-2154066

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

  

Trading

symbol(s):

  

Name of each exchange

on which registered:

Common Stock, $0.0075 par value   XOMA   The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share   XOMAP   The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)   XOMAO   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On May 9, 2023, XOMA Corporation issued a press release announcing its financial results for the quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Number    Description of Document
99.1    Press release entitled “XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy” dated May 9, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    XOMA CORPORATION
Date: May 9, 2023     By:  

/s/ THOMAS BURNS

      Thomas Burns
      Senior Vice President, Finance and Chief Financial Officer
 EX-99.1 2 d450885dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

First quarter with incoming cashflows from two commercial assets

Completed first royalty asset acquisition under new leadership

EMERYVILLE, Calif. – May 9, 2023 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 financial results and highlighted recent operational achievements as the Company accelerates XOMA’s differentiated biotech royalty and milestone acquisition strategy.

“We are increasing our efforts to be a provider of capital to emerging biotech companies, often enabling these companies to unlock value in the face of a challenging market backdrop for innovative, early stage companies,” stated Owen Hughes, Executive Chairman of XOMA. “In the first quarter, the team acted rapidly and decisively to add a second cashflow-generating, long-duration asset to XOMA’s milestone and royalty portfolio. We will continue to reinvest our incoming cashflows and milestone payments to accelerate our royalty monetization strategy.”

“The first five months of 2023 have demonstrated both the royalty potential within and the opportunities to grow our royalty and milestone aggregator business model. In February, we received a payment related to the commercial sales of Vabysmo® (faricimab) during the second half of 2022. In March, we acquired the IXINITY® [coagulation factor IX (recombinant)] commercial payment stream held by Aptevo and will begin recording those commercial payments in the second quarter of 2023,” said Brad Sitko, Chief Investment Officer of XOMA. “The team and I are actively identifying additional royalty and milestone acquisition agreements that can deliver significant value to XOMA and our shareholders.”

First Quarter 2023 Financial Results

XOMA recorded total revenues of $0.4 million for the first quarter of 2023, compared with $3.1 million in the first quarter of 2022. In the first quarter of 2022, XOMA recognized $2.0 million in revenue related to a milestone event under the Company’s license agreement with Rezolute and a $0.8 million milestone earned pursuant to its Takeda Collaboration Agreement. XOMA did not recognize milestone revenue during the three months ended March 31, 2023.

Research and development (“R&D”) expenses were $54,000 and $56,000, respectively, for the first quarters of 2023 and 2022.

General and administrative (“G&A”) expenses were $6.2 million for the first quarter of 2023, compared to $5.1 million for the first quarter of 2022. The increase of $1.1 million for the three months ended March 31, 2023, as compared to the corresponding period of 2022, was primarily due to a $0.6 million increase in stock-based compensation expense and a $0.3 million increase in consulting and legal costs.

In the first quarter of 2023, the Company reported arbitration settlement costs of $4.1 million, consisting of the costs incurred related to the arbitration proceeding settlement with one of its licensees.

In the first quarter of 2023, G&A expenses included $1.6 million in non-cash stock-based compensation expense, compared with $1.0 million in the first quarter of 2022. XOMA’s net cash used in operating activities during the first quarter of 2023 was $4.9 million, as compared with $1.0 million during the first quarter of 2022.

The Company reported total other income, net, of $0.4 million in the first quarter of 2023, as compared to total other expense, net, of $0.2 million in the corresponding period of 2022. The $0.6 million variation between the corresponding quarters reflects a $0.4 million increase in investment income and a $0.2 million change in fair value of equity securities XOMA holds in Rezolute, Inc.

Net loss for the first quarter of 2023 was $9.8 million, compared to a net loss of $2.3 million for the first quarter of 2022.

On March 31, 2023, XOMA had cash and cash equivalents of $44.3 million and no debt on its balance sheet. On December 31, 2022, XOMA had cash and cash equivalents of $57.8 million. On January 17, 2023, the Company paid cash dividends on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) equal to $0.53906 per share and cash dividends on the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) equal to $0.52344 per depositary share. In February 2023, XOMA received a cash payment from Roche, representing the second commercial payment from XOMA’s 0.5% commercial interest in the sales of Vabysmo®. This payment is reflected in the Company’s condensed consolidated balance sheet as of March 31, 2023, as a reduction of short-term royalty and commercial payment receivables.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general

corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA, the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, XOMA’s business forecast, the potential expansion and accelerated growth of XOMA’s portfolio, and the potential for this portfolio to generate sustained cashflows and positive returns over time. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except Vabysmo® (faricimab) and IXINITY® [coagulation factor IX (recombinant)], are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.

XOMA CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

 

     Three Months Ended
March 31,		  
     2023     2022  

Revenues:

     

Revenue from contracts with customers

    $ —       $ 2,750  

Revenue recognized under units-of-revenue method

      437       357  
  

 

 

    

 

 

  

Total revenues

      437       3,107  
  

 

 

    

 

 

  

Operating expenses:

     

Research and development

      54       56  

General and administrative

      6,196       5,116  

Arbitration settlement costs

      4,132       —    

Amortization of intangible assets

      225       —    
  

 

 

    

 

 

  

Total operating expenses

      10,607       5,172  
  

 

 

    

 

 

  

Loss from operations

      (10,170 )      (2,065 ) 

Other income (expense), net:

     

Other income (expense), net

      357       (215 ) 
  

 

 

    

 

 

  

Net loss and comprehensive loss

    $ (9,813 )    $ (2,280 ) 

Less: accumulated dividends on Series A and Series B preferred stock

      (1,368 )      (1,368 ) 
  

 

 

    

 

 

  

Net loss and comprehensive loss attributable to common stockholders, basic and diluted

    $ (11,181 )    $ (3,648 ) 
  

 

 

    

 

 

  

Basic and diluted net loss per share attributable to common stockholders

    $ (0.98 )    $ (0.32 ) 
  

 

 

    

 

 

  

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

      11,460       11,330  
  

 

 

    

 

 

  

XOMA CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

 

     March 31,
2023		     December 31,
2022		  
ASSETS    (unaudited)     (audited)  

Current assets:

     

Cash and cash equivalents

    $ 44,300     $ 57,826  

Short-term equity securities

      311       335  

Trade and other receivables, net

      6       1  

Short-term royalty and commercial payment receivables

      —         2,366  

Prepaid expenses and other current assets

      456       725  
  

 

 

    

 

 

  

Total current assets

      45,073       61,253  

Property and equipment, net

      6       7  

Operating lease right-of-use assets

      67       29  

Long-term royalty and commercial payment receivables

      73,333       63,683  

Intangible assets, net

      14,925       15,150  

Other assets - long term

      260       260  
  

 

 

    

 

 

  

Total assets

    $ 133,664     $ 140,382  
  

 

 

    

 

 

  
LIABILITIES AND STOCKHOLDERS’ EQUITY             

Current liabilities:

     

Accounts payable

    $ 437     $ 524  

Accrued and other liabilities

      6,127       2,918  

Contingent consideration under RPAs and CPPAs

      125       75  

Operating lease liabilities

      69       34  

Unearned revenue recognized under units-of-revenue method

      1,968       1,899  

Preferred stock dividend accrual

      1,368       1,368  
  

 

 

    

 

 

  

Total current liabilities

      10,094       6,818  

Unearned revenue recognized under units-of-revenue method – long-term

      9,044       9,550  
  

 

 

    

 

 

  

Total liabilities

      19,138       16,368  
  

 

 

    

 

 

  

Stockholders’ equity:

     

Preferred Stock, $0.05 par value, 1,000,000 shares authorized:

     

8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at March 31, 2023, and December 31, 2022

      49       49  

8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at March 31, 2023, and December 31, 2022

      —         —    

Convertible preferred stock, 5,003 issued and outstanding at March 31, 2023, and December 31, 2022

      —         —    

Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,460,968 and 11,454,025 shares issued and outstanding at March 31, 2023, and December 31, 2022, respectively

      86       86  

Additional paid-in capital

      1,306,596       1,306,271  

Accumulated deficit

      (1,192,205 )      (1,182,392 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      114,526       124,014  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 133,664     $ 140,382  
  

 

 

    

 

 

  

XOMA CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

 

     Three Months Ended
March 31,		  
     2023     2022  

Cash flows from operating activities:

     

Net loss

    $ (9,813 )    $ (2,280 ) 

Adjustments to reconcile net loss to net cash used in operating activities:

     

Stock-based compensation expense

      1,570       978  

Common stock contribution to 401(k)

      123       85  

Amortization of intangible assets

      225       —    

Depreciation

      1       2  

Non-cash lease expense

      47       42  

Change in fair value of equity securities

      24       227  

Changes in assets and liabilities:

     

Trade and other receivables, net

      (5 )      184  

Prepaid expenses and other assets

      269       204  

Accounts payable and accrued liabilities

      3,122       45  

Income taxes payable

      —         (91 ) 

Operating lease liabilities

      (50 )      (48 ) 

Unearned revenue recognized under units-of-revenue method

      (437 )      (357 ) 
  

 

 

    

 

 

  

Net cash used in operating activities

      (4,924 )      (1,009 ) 
  

 

 

    

 

 

  

Cash flows from investing activities:

     

Payments of consideration under RPAs and CPPAs

      (9,600 )      (5,000 ) 

Receipts under RPAs and CPPAs

      2,366       —    
  

 

 

    

 

 

  

Net cash used in investing activities

      (7,234 )      (5,000 ) 
  

 

 

    

 

 

  

Cash flows from financing activities:

     

Payment of preferred stock dividends

      (1,368 )      (1,368 ) 

Proceeds from exercise of options and other share-based compensation

      —         1,606  

Taxes paid related to net share settlement of equity awards

      —         (973 ) 
  

 

 

    

 

 

  

Net cash used in financing activities

      (1,368 )      (735 ) 
  

 

 

    

 

 

  

Net decrease in cash, cash equivalents and restricted cash

      (13,526 )      (6,744 ) 

Cash, cash equivalents and restricted cash at the beginning of the period

      57,826       95,377  
  

 

 

    

 

 

  

Cash, cash equivalents and restricted cash at the end of the period

    $ 44,300     $ 88,633  
  

 

 

    

 

 

  

Supplemental Cash Flow Information:

     

Cash paid for taxes

    $ —       $ 95  

Right-of-use assets obtained in exchange for operating lease liabilities

    $ 85     $ —    

Non-cash investing and financing activities:

     

Preferred stock dividend accrual

    $ 1,368     $ 1,368  

Estimated fair value of contingent consideration under the Aptevo CPPA

    $ 50     $ —    

 

###

 

XOMA Investor Contact

    XOMA Media Contact

Juliane Snowden

   

Kathy Vincent

XOMA Corporation

   

KV Consulting & Management

+1 646-438-9754

   

+1 310-403-8951

juliane.snowden@xoma.com    kathy@kathyvincent.com
 EX-101.SCH 3 xomao-20230509.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 xomao-20230509_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 xomao-20230509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] EX-101.PRE 6 xomao-20230509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g450885g09f34.jpg GRAPHIC begin 644 g450885g09f34.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 09, 2023
Document And Entity Information [Line Items]  
Entity Registrant Name XOMA Corp
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0000791908
Document Type 8-K
Document Period End Date May 09, 2023
Entity File Number 001-39801
Entity Tax Identification Number 52-2154066
Entity Address, Address Line One 2200 Powell Street
Entity Address, Address Line Two Suite 310
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code (510)
Local Phone Number 204-7200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, $0.0075 par value
Trading Symbol XOMA
Security Exchange Name NASDAQ
Series A Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share
Trading Symbol XOMAP
Security Exchange Name NASDAQ
Series B Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)
Trading Symbol XOMAO
Security Exchange Name NASDAQ
XML 9 d450885d8k_htm.xml IDEA: XBRL DOCUMENT 0000791908 2023-05-09 2023-05-09 0000791908 us-gaap:CommonStockMember 2023-05-09 2023-05-09 0000791908 us-gaap:SeriesAPreferredStockMember 2023-05-09 2023-05-09 0000791908 us-gaap:SeriesBPreferredStockMember 2023-05-09 2023-05-09 XOMA Corp DE false 0000791908 8-K 2023-05-09 001-39801 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 (510) 204-7200 false false false false Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 23 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, dei:EntityRegistrantName - d450885d8k.htm 7 d450885d8k.htm d450885dex991.htm xomao-20230509.xsd xomao-20230509_def.xml xomao-20230509_lab.xml xomao-20230509_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d450885d8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "xomao-20230509_def.xml" ] }, "inline": { "local": [ "d450885d8k.htm" ] }, "labelLink": { "local": [ "xomao-20230509_lab.xml" ] }, "presentationLink": { "local": [ "xomao-20230509_pre.xml" ] }, "schema": { "local": [ "xomao-20230509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 3, "nsprefix": "xomao", "nsuri": "http://imetrix.edgar-online.com/20230509", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d450885d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d450885d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "xomao_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://imetrix.edgar-online.com/20230509", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "xomao_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://imetrix.edgar-online.com/20230509", "presentation": [ "http://imetrix.edgar-online.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001193125-23-138911-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-138911-xbrl.zip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end